Stockreport

Actinium Pharmaceuticals Highlights Antibody Radiation Conjugate Program Developments and Reports Financial Results for the Third Quarter 2024 [Yahoo! Finance]

Actinium Pharmaceuticals, Inc. (Delaware)  (ATNM) 
NASDAQ:AMEX Investor Relations: ir.actiniumpharma.com
PDF - Actimab-A selected for National Cancer Institute's recently opened myeloMATCH precision medicines program for patients with acute myeloid leukemia and myelodysplastic [Read more]